2024-09-19
ENA first public
ERC000050
ENA-CHECKLIST
EMBL Heidelberg
INSDC center name
public
INSDC status
ERS21060428
SRA accession
spire_mag_01020771
Submitter Id
Many fragments with little to no review of assembly other than reporting of standard assembly statistics
assembly quality
megahit 1.2.9
assembly software
default
binning parameters
metabat 2.12.1
binning software
human digestive system
broad-scale environmental context
EBI-EMG
broker name
2014-08-04
collection date
58.92
%
completeness score
checkm2 0.1.3
completeness software
0.97
%
contamination score
This sample represents a Third Party Annotation (TPA) binned metagenome assembled from the metagenomic run ERR2451938 of study ERP107673.
description
not specified
environmental medium
Denmark
geographic location (country and/or sea)
55.69813700
DD
geographic location (latitude)
12.56136100
DD
geographic location (longitude)
metagenome-assembled genome
investigation type
human gut metagenome
isolation_source
human gut
local environmental context
human gut metagenome
metagenomic source
Phocaeicola vulgatus
organism
We have recently published data regarding a randomized cross-over intervention using AXOS and poly-unsaturated fatty acids (PUFA) on a cohort of subjects with overweight and metabolic syndrome (MetS). By using a bacterial 16S amplicons based approach we observed the already known bifidogenic effect of AXOS in the human gut. Moreover, we showed for the first time that intake of ~10 g/day AXOS, for 4 weeks, drives significant changes in the structure of the human gut microbiota as a whole by concomitantly increasing the abundance of pivotal species for butyrate production. Our data also indicated that minor effects of AXOS intake had place at physiological and metabolic levels by inspection of several clinical parameters. As a consequence, we aimed the present study to characterize a more detailed response from the human body to AXOS in order to gain insights with respect to the less visible metabolic effects associated with consumption of this type of dietary fiber. For such aim, we have analyzed the group of responders to AXOS consumption (to whom the gut microbiota was significantly altered) from our early study (first period/arm of the AXOS cross-over design).Registration: Registered under ClinicalTrials.gov Identifier no.NCT02215343
project name
SAMEA104725008
sample derived from
Phocaeicola vulgatus
scientific_name
Illumina HiSeq 2500
sequencing method
multi-marker approach
taxonomic identity marker
binned metagenome: spire_mag_01020771
title